img

Global Mucopolysaccharidosis Therapeutics Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Mucopolysaccharidosis Therapeutics Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

MPS, also known as mucopolysaccharidosis, refers to a group of key rare metabolic disorders which is caused by the absence, deficiency or malfunctioning of lysosomal enzymes called glycosaminoglycan (GAGs).
Mucopolysaccharidosis Therapeutics report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Mucopolysaccharidosis Therapeutics market is projected to reach US$ 3392.8 million in 2029, increasing from US$ 2381 million in 2022, with the CAGR of 5.2% during the period of 2024 to 2029. Demand from Hospital and Clinic are the major drivers for the industry.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Mucopolysaccharidosis Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


Shire (Takeda Pharmaceutical Company Limited)
Denali Therapeutics
ArmaGen
REGENXBIO Inc.
Sangamo Therapeutics
BioMarin
Lysogene
Abeona Therapeutics Inc.
Ultragenyx Pharmaceutical
Genzyme Corporation
Segment by Type
Intravenous
Intracerebroventricular (ICV)

Segment by Application


Hospital
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Mucopolysaccharidosis Therapeutics market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Mucopolysaccharidosis Therapeutics introduction, etc. Mucopolysaccharidosis Therapeutics Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Mucopolysaccharidosis Therapeutics market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Market Overview of Mucopolysaccharidosis Therapeutics
1.1 Mucopolysaccharidosis Therapeutics Market Overview
1.1.1 Mucopolysaccharidosis Therapeutics Product Scope
1.1.2 Mucopolysaccharidosis Therapeutics Market Status and Outlook
1.2 Global Mucopolysaccharidosis Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Mucopolysaccharidosis Therapeutics Market Size by Region (2018-2029)
1.4 Global Mucopolysaccharidosis Therapeutics Historic Market Size by Region (2018-2024)
1.5 Global Mucopolysaccharidosis Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Mucopolysaccharidosis Therapeutics Market Size (2018-2029)
1.6.1 North America Mucopolysaccharidosis Therapeutics Market Size (2018-2029)
1.6.2 Europe Mucopolysaccharidosis Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size (2018-2029)
1.6.4 Latin America Mucopolysaccharidosis Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size (2018-2029)
2 Mucopolysaccharidosis Therapeutics Market by Type
2.1 Introduction
2.1.1 Intravenous
2.1.2 Intracerebroventricular (ICV)
2.2 Global Mucopolysaccharidosis Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Mucopolysaccharidosis Therapeutics Historic Market Size by Type (2018-2024)
2.2.2 Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Mucopolysaccharidosis Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Mucopolysaccharidosis Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Mucopolysaccharidosis Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Mucopolysaccharidosis Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Mucopolysaccharidosis Therapeutics Revenue Breakdown by Type (2018-2029)
3 Mucopolysaccharidosis Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Other
3.2 Global Mucopolysaccharidosis Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Mucopolysaccharidosis Therapeutics Historic Market Size by Application (2018-2024)
3.2.2 Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Mucopolysaccharidosis Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Mucopolysaccharidosis Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Mucopolysaccharidosis Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Mucopolysaccharidosis Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Mucopolysaccharidosis Therapeutics Revenue Breakdown by Application (2018-2029)
4 Mucopolysaccharidosis Therapeutics Competition Analysis by Players
4.1 Global Mucopolysaccharidosis Therapeutics Market Size by Players (2018-2024)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Mucopolysaccharidosis Therapeutics as of 2022)
4.3 Date of Key Players Enter into Mucopolysaccharidosis Therapeutics Market
4.4 Global Top Players Mucopolysaccharidosis Therapeutics Headquarters and Area Served
4.5 Key Players Mucopolysaccharidosis Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Mucopolysaccharidosis Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Shire (Takeda Pharmaceutical Company Limited)
5.1.1 Shire (Takeda Pharmaceutical Company Limited) Profile
5.1.2 Shire (Takeda Pharmaceutical Company Limited) Main Business
5.1.3 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Products, Services and Solutions
5.1.4 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Revenue (US$ Million) & (2018-2024)
5.1.5 Shire (Takeda Pharmaceutical Company Limited) Recent Developments
5.2 Denali Therapeutics
5.2.1 Denali Therapeutics Profile
5.2.2 Denali Therapeutics Main Business
5.2.3 Denali Therapeutics Mucopolysaccharidosis Therapeutics Products, Services and Solutions
5.2.4 Denali Therapeutics Mucopolysaccharidosis Therapeutics Revenue (US$ Million) & (2018-2024)
5.2.5 Denali Therapeutics Recent Developments
5.3 ArmaGen
5.3.1 ArmaGen Profile
5.3.2 ArmaGen Main Business
5.3.3 ArmaGen Mucopolysaccharidosis Therapeutics Products, Services and Solutions
5.3.4 ArmaGen Mucopolysaccharidosis Therapeutics Revenue (US$ Million) & (2018-2024)
5.3.5 REGENXBIO Inc. Recent Developments
5.4 REGENXBIO Inc.
5.4.1 REGENXBIO Inc. Profile
5.4.2 REGENXBIO Inc. Main Business
5.4.3 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Products, Services and Solutions
5.4.4 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Revenue (US$ Million) & (2018-2024)
5.4.5 REGENXBIO Inc. Recent Developments
5.5 Sangamo Therapeutics
5.5.1 Sangamo Therapeutics Profile
5.5.2 Sangamo Therapeutics Main Business
5.5.3 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Products, Services and Solutions
5.5.4 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Revenue (US$ Million) & (2018-2024)
5.5.5 Sangamo Therapeutics Recent Developments
5.6 BioMarin
5.6.1 BioMarin Profile
5.6.2 BioMarin Main Business
5.6.3 BioMarin Mucopolysaccharidosis Therapeutics Products, Services and Solutions
5.6.4 BioMarin Mucopolysaccharidosis Therapeutics Revenue (US$ Million) & (2018-2024)
5.6.5 BioMarin Recent Developments
5.7 Lysogene
5.7.1 Lysogene Profile
5.7.2 Lysogene Main Business
5.7.3 Lysogene Mucopolysaccharidosis Therapeutics Products, Services and Solutions
5.7.4 Lysogene Mucopolysaccharidosis Therapeutics Revenue (US$ Million) & (2018-2024)
5.7.5 Lysogene Recent Developments
5.8 Abeona Therapeutics Inc.
5.8.1 Abeona Therapeutics Inc. Profile
5.8.2 Abeona Therapeutics Inc. Main Business
5.8.3 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Products, Services and Solutions
5.8.4 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Revenue (US$ Million) & (2018-2024)
5.8.5 Abeona Therapeutics Inc. Recent Developments
5.9 Ultragenyx Pharmaceutical
5.9.1 Ultragenyx Pharmaceutical Profile
5.9.2 Ultragenyx Pharmaceutical Main Business
5.9.3 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Products, Services and Solutions
5.9.4 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Revenue (US$ Million) & (2018-2024)
5.9.5 Ultragenyx Pharmaceutical Recent Developments
5.10 Genzyme Corporation
5.10.1 Genzyme Corporation Profile
5.10.2 Genzyme Corporation Main Business
5.10.3 Genzyme Corporation Mucopolysaccharidosis Therapeutics Products, Services and Solutions
5.10.4 Genzyme Corporation Mucopolysaccharidosis Therapeutics Revenue (US$ Million) & (2018-2024)
5.10.5 Genzyme Corporation Recent Developments
6 North America
6.1 North America Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Mucopolysaccharidosis Therapeutics Market Dynamics
11.1 Mucopolysaccharidosis Therapeutics Industry Trends
11.2 Mucopolysaccharidosis Therapeutics Market Drivers
11.3 Mucopolysaccharidosis Therapeutics Market Challenges
11.4 Mucopolysaccharidosis Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Mucopolysaccharidosis Therapeutics Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029
Table 2. Global Mucopolysaccharidosis Therapeutics Market Size by Region (2018-2024) & (US$ Million)
Table 3. Global Mucopolysaccharidosis Therapeutics Market Size Share by Region (2018-2024)
Table 4. Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 5. Global Mucopolysaccharidosis Therapeutics Forecasted Market Size Share by Region (2024-2029)
Table 6. Global Mucopolysaccharidosis Therapeutics Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029
Table 7. Global Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2024) & (US$ Million)
Table 8. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2018-2024)
Table 9. Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 10. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2024-2029)
Table 11. North America Mucopolysaccharidosis Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 12. North America Mucopolysaccharidosis Therapeutics Revenue by Type (2024-2029) & (US$ Million)
Table 13. Europe Mucopolysaccharidosis Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 14. Europe Mucopolysaccharidosis Therapeutics Revenue by Type (2024-2029) & (US$ Million)
Table 15. Asia-Pacific Mucopolysaccharidosis Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 16. Asia-Pacific Mucopolysaccharidosis Therapeutics Revenue by Type (2024-2029) & (US$ Million)
Table 17. Latin America Mucopolysaccharidosis Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 18. Latin America Mucopolysaccharidosis Therapeutics Revenue by Type (2024-2029) & (US$ Million)
Table 19. Middle East and Africa Mucopolysaccharidosis Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 20. Middle East and Africa Mucopolysaccharidosis Therapeutics Revenue by Type (2024-2029) & (US$ Million)
Table 21. Global Mucopolysaccharidosis Therapeutics Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029
Table 22. Global Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2024) & (US$ Million)
Table 23. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2018-2024)
Table 24. Global Mucopolysaccharidosis Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 25. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2024-2029)
Table 26. North America Mucopolysaccharidosis Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 27. North America Mucopolysaccharidosis Therapeutics Revenue by Application (2024-2029) & (US$ Million)
Table 28. Europe Mucopolysaccharidosis Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 29. Europe Mucopolysaccharidosis Therapeutics Revenue by Application (2024-2029) & (US$ Million)
Table 30. Asia-Pacific Mucopolysaccharidosis Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 31. Asia-Pacific Mucopolysaccharidosis Therapeutics Revenue by Application (2024-2029) & (US$ Million)
Table 32. Latin America Mucopolysaccharidosis Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 33. Latin America Mucopolysaccharidosis Therapeutics Revenue by Application (2024-2029) & (US$ Million)
Table 34. Middle East and Africa Mucopolysaccharidosis Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 35. Middle East and Africa Mucopolysaccharidosis Therapeutics Revenue by Application (2024-2029) & (US$ Million)
Table 36. Global Mucopolysaccharidosis Therapeutics Revenue (US$ Million) by Players (2018-2024)
Table 37. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Players (2018-2024)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Mucopolysaccharidosis Therapeutics as of 2022)
Table 39. Date of Key Players Enter into Mucopolysaccharidosis Therapeutics Market
Table 40. Global Mucopolysaccharidosis Therapeutics Key Players Headquarters and Area Served
Table 41. Mucopolysaccharidosis Therapeutics Product Solution and Service
Table 42. Global Mucopolysaccharidosis Therapeutics Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Shire (Takeda Pharmaceutical Company Limited) Basic Information List
Table 45. Shire (Takeda Pharmaceutical Company Limited) Description and Business Overview
Table 46. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Products, Services and Solutions
Table 47. Revenue (US$ Million) in Mucopolysaccharidosis Therapeutics Business of Shire (Takeda Pharmaceutical Company Limited) (2018-2024)
Table 48. Shire (Takeda Pharmaceutical Company Limited) Recent Developments
Table 49. Denali Therapeutics Basic Information List
Table 50. Denali Therapeutics Description and Business Overview
Table 51. Denali Therapeutics Mucopolysaccharidosis Therapeutics Products, Services and Solutions
Table 52. Revenue (US$ Million) in Mucopolysaccharidosis Therapeutics Business of Denali Therapeutics (2018-2024)
Table 53. Denali Therapeutics Recent Developments
Table 54. ArmaGen Basic Information List
Table 55. ArmaGen Description and Business Overview
Table 56. ArmaGen Mucopolysaccharidosis Therapeutics Products, Services and Solutions
Table 57. Revenue (US$ Million) in Mucopolysaccharidosis Therapeutics Business of ArmaGen (2018-2024)
Table 58. ArmaGen Recent Developments
Table 59. REGENXBIO Inc. Basic Information List
Table 60. REGENXBIO Inc. Description and Business Overview
Table 61. REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Products, Services and Solutions
Table 62. Revenue (US$ Million) in Mucopolysaccharidosis Therapeutics Business of REGENXBIO Inc. (2018-2024)
Table 63. REGENXBIO Inc. Recent Developments
Table 64. Sangamo Therapeutics Basic Information List
Table 65. Sangamo Therapeutics Description and Business Overview
Table 66. Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Products, Services and Solutions
Table 67. Revenue (US$ Million) in Mucopolysaccharidosis Therapeutics Business of Sangamo Therapeutics (2018-2024)
Table 68. Sangamo Therapeutics Recent Developments
Table 69. BioMarin Basic Information List
Table 70. BioMarin Description and Business Overview
Table 71. BioMarin Mucopolysaccharidosis Therapeutics Products, Services and Solutions
Table 72. Revenue (US$ Million) in Mucopolysaccharidosis Therapeutics Business of BioMarin (2018-2024)
Table 73. BioMarin Recent Developments
Table 74. Lysogene Basic Information List
Table 75. Lysogene Description and Business Overview
Table 76. Lysogene Mucopolysaccharidosis Therapeutics Products, Services and Solutions
Table 77. Revenue (US$ Million) in Mucopolysaccharidosis Therapeutics Business of Lysogene (2018-2024)
Table 78. Lysogene Recent Developments
Table 79. Abeona Therapeutics Inc. Basic Information List
Table 80. Abeona Therapeutics Inc. Description and Business Overview
Table 81. Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Products, Services and Solutions
Table 82. Revenue (US$ Million) in Mucopolysaccharidosis Therapeutics Business of Abeona Therapeutics Inc. (2018-2024)
Table 83. Abeona Therapeutics Inc. Recent Developments
Table 84. Ultragenyx Pharmaceutical Basic Information List
Table 85. Ultragenyx Pharmaceutical Description and Business Overview
Table 86. Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Products, Services and Solutions
Table 87. Revenue (US$ Million) in Mucopolysaccharidosis Therapeutics Business of Ultragenyx Pharmaceutical (2018-2024)
Table 88. Ultragenyx Pharmaceutical Recent Developments
Table 89. Genzyme Corporation Basic Information List
Table 90. Genzyme Corporation Description and Business Overview
Table 91. Genzyme Corporation Mucopolysaccharidosis Therapeutics Products, Services and Solutions
Table 92. Revenue (US$ Million) in Mucopolysaccharidosis Therapeutics Business of Genzyme Corporation (2018-2024)
Table 93. Genzyme Corporation Recent Developments
Table 94. North America Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2024) & (US$ Million)
Table 95. North America Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 96. Europe Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2024) & (US$ Million)
Table 97. Europe Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 98. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 99. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Region (2018-2024) & (US$ Million)
Table 100. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size by Region (2024-2029) & (US$ Million)
Table 101. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Share by Region (2018-2024)
Table 102. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Share by Region (2024-2029)
Table 103. Latin America Mucopolysaccharidosis Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 104. Latin America Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2024) & (US$ Million)
Table 105. Latin America Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 106. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 107. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2024) & (US$ Million)
Table 108. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 109. Mucopolysaccharidosis Therapeutics Market Trends
Table 110. Mucopolysaccharidosis Therapeutics Market Drivers
Table 111. Mucopolysaccharidosis Therapeutics Market Challenges
Table 112. Mucopolysaccharidosis Therapeutics Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Mucopolysaccharidosis Therapeutics Market Size Year-over-Year 2018-2029 & (US$ Million)
Figure 2. Global Mucopolysaccharidosis Therapeutics Market Size (US$ Million), 2018 VS 2022 VS 2029
Figure 3. Global Mucopolysaccharidosis Therapeutics Market Share by Regions: 2022 VS 2029
Figure 4. Global Mucopolysaccharidosis Therapeutics Forecasted Market Size Share by Region (2024-2029)
Figure 5. North America Mucopolysaccharidosis Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 6. Europe Mucopolysaccharidosis Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 7. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 8. Latin America Mucopolysaccharidosis Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 9. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 10. Product Picture of Intravenous
Figure 11. Global Intravenous Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 12. Product Picture of Intracerebroventricular (ICV)
Figure 13. Global Intracerebroventricular (ICV) Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 14. Global Mucopolysaccharidosis Therapeutics Market Size Share by Type: 2022 & 2029
Figure 15. North America Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2018-2029)
Figure 16. Europe Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2018-2029)
Figure 17. Asia-Pacific Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2018-2029)
Figure 18. Latin America Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2018-2029)
Figure 19. Middle East and Africa Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2018-2029)
Figure 20. Hospital Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 21. Clinic Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 22. Other Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 23. Global Mucopolysaccharidosis Therapeutics Market Size Share by Application: 2022 & 2029
Figure 24. North America Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2018-2029)
Figure 25. Europe Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2018-2029)
Figure 26. Asia-Pacific Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2018-2029)
Figure 27. Latin America Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2018-2029)
Figure 28. Middle East and Africa Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2018-2029)
Figure 29. Mucopolysaccharidosis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 30. Global Top 5 and Top 10 Players Mucopolysaccharidosis Therapeutics Market Share in 2022
Figure 31. North America Mucopolysaccharidosis Therapeutics Market Share by Country (2018-2029)
Figure 32. United States Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 33. Canada Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 34. Germany Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 35. France Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 36. U.K. Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 37. Italy Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 38. Russia Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 39. Nordic Countries Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 40. Asia-Pacific Mucopolysaccharidosis Therapeutics Market Share by Region (2018-2029)
Figure 41. China Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 42. Japan Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 43. South Korea Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 44. Southeast Asia Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 45. India Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 46. Australia Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 47. Latin America Mucopolysaccharidosis Therapeutics Market Share by Country (2018-2029)
Figure 48. Mexico Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 49. Brazil Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 50. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Share by Country (2018-2029)
Figure 51. Turkey Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 53. UAE Mucopolysaccharidosis Therapeutics Market Size (2018-2029) & (US$ Million)
Figure 54. Bottom-up and Top-down Approaches for This Report